Ionis Pharmaceuticals (IONS) Soars 17.32% on FDA Approval

Ionis Pharmaceuticals (IONS) surged 17.32% in pre-market trading on September 2, 2025, driven by significant developments in its drug pipeline and regulatory approvals.

Ionis Pharmaceuticals received FDA approval for its hereditary angioedema (HAE) drug, marking a major milestone for the company. This approval is expected to boost the company's revenue and market position. Additionally, Piper Sandler has lifted its target price for Ionis Pharmaceuticals, reflecting the positive outlook on the company's prospects.

Another key development is the FDA's decision on Donidalorsen, an investigational RNA-targeted medicine developed by Ionis Pharmaceuticals. The decision, expected on August 21, 2025, could further impact the company's stock performance. Donidalorsen is a promising drug that targets specific RNA sequences, offering potential therapeutic benefits for various diseases.